Form 4: Corcept CDO Sells 4,500 Shares Under Pre-Arranged Plan

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 4,500 shares of common stock for approximately $80.90 per share as part of a pre-scheduled trading plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported a sale of company common stock.
• The transaction involved the disposition of 4,500 shares of common stock.
• The shares were sold at a weighted average price of $80.9045 per share.
• Individual sale prices ranged from $80.81 to $81.085 per share.
• Following this transaction, William Guyer beneficially owns 787 shares of Corcept Therapeutics common stock directly.
• The transaction was executed on November 25, 2025.
• The sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the disclosure that it was executed under a Rule 10b5-1 plan mitigates concerns, as it indicates a pre-scheduled transaction rather than a discretionary sale based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a slight negative signal regarding management's immediate outlook on the stock's valuation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a routine disclosure for a publicly traded biotechnology company.

Stakeholder Impact

• Shareholders: The sale by a Chief Development Officer could be interpreted by some shareholders as a minor signal, but its execution under a 10b5-1 plan suggests it's not based on new material information, thus limiting significant impact.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider trading report.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider stock sale and does not provide new fundamental information about Corcept Therapeutics' operations, financial health, or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this disclosure. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Sale, William Guyer, Chief Development Officer, 10b5-1 Plan